5-149351256-G-A
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_152407.4(GRPEL2):c.652G>A(p.Ala218Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000686 in 1,457,580 control chromosomes in the GnomAD database, with no homozygous occurrence. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Consequence
NM_152407.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GRPEL2 | ENST00000329271.8 | c.652G>A | p.Ala218Thr | missense_variant | Exon 4 of 4 | 1 | NM_152407.4 | ENSP00000329558.3 | ||
GRPEL2 | ENST00000416916.2 | c.*201G>A | 3_prime_UTR_variant | Exon 3 of 3 | 2 | ENSP00000397302.2 | ||||
GRPEL2 | ENST00000507562.1 | n.782G>A | non_coding_transcript_exon_variant | Exon 4 of 4 | 3 | |||||
GRPEL2-AS1 | ENST00000521295.1 | n.119-2858C>T | intron_variant | Intron 1 of 1 | 3 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome AF: 6.86e-7 AC: 1AN: 1457580Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 724170
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not specified Uncertain:1
The c.652G>A (p.A218T) alteration is located in exon 4 (coding exon 4) of the GRPEL2 gene. This alteration results from a G to A substitution at nucleotide position 652, causing the alanine (A) at amino acid position 218 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.